New combo aims to unleash immune system on tough melanoma
NCT ID NCT03161431
First seen Dec 29, 2025 · Last updated May 08, 2026 · Updated 24 times
Summary
This early-stage study tests a new drug, SX-682, in people with advanced melanoma that has spread. The drug is designed to block cancer from hiding from the immune system. Participants first take SX-682 alone, then add the immunotherapy pembrolizumab for up to two years. The goal is to find a safe dose and see if the combination helps shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Wilmot Cancer Institute - University of Rochester
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.